EGFR and non-small cell lung carcinoma: All patients reported having stage 3b or 4 NSCLC at the time of the survey and were considered to be EGFR‐positive based on a self‐reported positive test result (n = 49) or indicated they had received targeted therapy against EGFR mutation (n = 5).